China Biologic Products Holdings Inc

China Biologic Products — Investor Presentation (February 2008)

27 slides from China Biologic Products's investor presentation, Feb 19, 2008

  1. Slide 1: China Biologic Products, Inc. – February 2008

    Slide 1: China Biologic Products, Inc. – February 2008

    February 2008 6, China Biologic Products, Inc. A profitable, rapidly growing plasma-based biopharmaceutical products company in China

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    @@ Safe Harbor Statement CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation includes or incorporates by reference statements that constitute forward- looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securi

  3. Slide 3: Price and Key Financial Statistics

    Slide 3: Price and Key Financial Statistics

    Price (2/14/08 $5.18 Market Capitalization: $102.6M Revenues (ttm): $32.5M Net income (ttm): $8.0M Wtd Avg Diluted Shares as of 9/30/07 21.4M Diluted Earnings Per Share (ttm) $0.37 & China Biologic Products, Inc. 3

  4. Slide 4: Company Overview

    Slide 4: Company Overview

    @ Company Overview = ¢ Our Mission: To be the leading provider of plasma-based biopharmaceutical products in China Only approved manufacturer of plasma-based biopharmaceutical products in Shandong, China, the second largest province with a population of 93 million ¢ Plasma-based Human Albumin is use

  5. Slide 5: Investment Highlights

    Slide 5: Investment Highlights

    Investment Highlights ¢@ Rising demand for plasma-based products ¢ Stringent regulatory requirements, consolidating market creates tight supply conditions ¢@ China Biologic has secured limited raw materials supply ¢ One of first companies to receive Good Manufacturing Practices (GMP) Certification i

  6. Slide 6: Principal Products

    Slide 6: Principal Products

    ® ‘Principal Products —s China Biologic’s Products are Essential to Health Care == Human Albumin plasma protein formed in the liver and accounts for about 60% of protein =| in blood. Applications include emergency blood loss, burns, volume replacement during and after surgery, improvement of wound h

  7. Slide 7: High Demand for Products

    Slide 7: High Demand for Products

    @Migh Demand for Products oduct: Toubaopaitongna Cefoperazone Sodium! Amoxicillin Sodium Levofloxacin 2,321 288 Cefuroxime 1,994 247 Ceftazidime 1,620 201 Taxol 1,569 194 Azithromycin 1,471 182 Filgrastim 1,328 165 Thymosin 1,284 159 Human Album 1,266 57 Sodium Chloride 1,260 156 Source: Gousen rese

  8. Slide 8: Under Penetrated Market

    Slide 8: Under Penetrated Market

    = Under Penetrated Market Plasma Market: China vs. Developed Nations ie More developed eee (Per million population) Albumin 55kg 200-300kg 18%-28% IMIG (Intravenous a Immunoglobulin G) 1kg 10kg 10% Factor VIll 0.110 41U 10% Range of Plasma Products Used Region Human Albumin WEesT xo Clotting Factors

  9. Slide 9: Revenue Breakdown

    Slide 9: Revenue Breakdown

    @ @Revenue Breakdown Product Sales Mix & Product Growth Rates % of 2008 | 9 Months 2007 PRODUCT 9F 2006 |, oF2007 | Volume Revenues Breakdown Sales | Growth Rate for 9 Mos. of 2007 Human y peer 75.49% 69.3% 23.1% 12.24% 14.8% 104.2% Human Immunoglobulin for Intravenous Injection esc es may 4.23% 5.5

  10. Slide 10: Rising Demand and Limited Supply

    Slide 10: Rising Demand and Limited Supply

    Rising Demand and Limited Supply Stringent regulatory requirements, only 34 approved manufacturers left in China Half are not competitive due to lack of plasma supply, obsolete production facilities, smaller product portfolios No. 1 market share is only 15% China Biologic ranks 5t" Only 100 licensed

  11. Slide 11: Mandates Strengthen Market Structure/Drive Consolidation

    Slide 11: Mandates Strengthen Market Structure/Drive Consolidation

    Mandates Strengthen Market tructure/Drive Consolidation ; Heightened safety and hygienic standards Stringent GMP Certification required for biopharmaceutical Regulation by manufacturers, including blood collection stations Government Restriction of imported products from international sources Limite

  12. Slide 12: Stringent Quality Control

    Slide 12: Stringent Quality Control

    Stringent Quality Control > One of first plasma-based manufacturers in China to receive GMP certification (1999) > Awarded Advanced High-tech Enterprise Certification by the Department of Science and Technology of Shandong Province (2005) > Awarded Advanced High-tech Enterprise Certification by the

  13. Slide 13: Secure the supply of plasma

    Slide 13: Secure the supply of plasma

    Secure the supply of plasma «Acquire competitors or other biologic related companies Further strengthen research and development capability Focus on new products and regional expansion & China Biologic Products, Inc. 13

  14. Slide 14: Securing the Plasma Supply

    Slide 14: Securing the Plasma Supply

    Securing the Plasma Supply Securing the plasma supply December 2006 - Acquired the assets of five of the six plasma collection stations in Shandong Province around 280 tons of plasma supply February and April 2007 — Acquired the assets of two stations in Guangxi Province Further acquisition of colle

  15. Slide 15: Focus on R&D

    Slide 15: Focus on R&D

    Focus on R&D On-going R&D Objectives + Broaden the breadth and depth of our portfolio of plasma-based biopharmaceutical products > Enhance the yield per unit volume of plasma through new collection techniques ~ Maximize manufacturing efficiency and safety ~ Promote product safety through implementat

  16. Slide 16: New Product Pipeline

    Slide 16: New Product Pipeline

    @New Product Pipeline Product Status Human Hepatitis B Immunoglobulin Clinical study approved by SFDA (pH 4) for Intravenous Injection Human Albumin(12.5g/vial) Accredited by SFDA-CDE Human Immunoglobulin (5givial) Accredited by SFDA-CDE for Intravenous Injection Human Prothrombin Complex Accomplish

  17. Slide 17: Product & Geographic Expansion

    Slide 17: Product & Geographic Expansion

    Product & Geographic Expansion Increase Customer Penetration and Expand into Other Provinces @ Increase penetration at existing customers with new products « Expand geographic reach + Shandong Province accounts for roughly half of total revenue > Continue marketing efforts in Jiangsu, Zhejiang, Hena

  18. Slide 18: Management Profiles

    Slide 18: Management Profiles

    @ Management Profiles Ms. Siu Ling Chan, Chairwoman of the Board + Director of Shandong Taibang (Chinese operating subsidiary) since April 2008 + Previously senior management of a number of companies + Master of Statistics from Xiamen University Stanley Wong, CEO + Over 20 years of experience in the

  19. Slide 19: Financial Highlights

    Slide 19: Financial Highlights

    Financial Highlights ina Biologic Products, Inc. & bis 19

  20. Slide 20: Revenues

    Slide 20: Revenues

    Revenues CAGR (USD $ in Thousands) 65% 25,000 an increase of 69%, 20,000 15,000 11,559 10,000 8,163 5,000 0 2004 2005 2006 9 Mos. of 2006 9 Mos. of 2007 Note: Revenues of FY 2004 for Shandong Taibang Biological Products Co., Ltd., were translated at RMB7.60 to USS1.00. China Biologic Products, Inc.

  21. Slide 21: Rising Net Income

    Slide 21: Rising Net Income

    @ Rising Net Income jet Incom CAGR (USD $ in Thousands) 7,601 6,000 an increase Of 125%, 5,000 4,000 3,000 2,000 1,310 “ = | | | _ 2004 2005 9Mos. of 2006 9 Mos. of 2007 EP: $0.03 $0.07 $0.35 Note: Net income of FY 2004 for Shandong Taibang Biological Products Co., Ltd., were translated at RMB7.60 t

  22. Slide 22: Income Statement

    Slide 22: Income Statement

    — @ @ Income Statement Consolidated Income Statement Year Ended Dec 34 Nine Months Ended Sep 30 ($ in Millions) 2005 Revenues 11.6 22.2 15.1 25.4 Gross Profit 5.4 12.6 8.6 417.4 Operating income 2.5 6.2 55 114 Net income 1.3 3.8 3.4 7.6 Weighted average number of shares Diluted EPS - diluted $0.07 $

  23. Slide 23: Balance Sheet

    Slide 23: Balance Sheet

    @.8 Balance Sheet Consolidated Balance Sheets Year Ended Dec 34 ‘Sep 30 ($ in Millions) 2005 2006 2007 Cash $0.6 $4.3 $6.1 Total Current Assets $9.7 $15.5 $18.5 Total Assets $15.7 $24.5 $34.5 Total Current Liabilities $12.1 $8.8 $8.9 Total Stockholder’s Equity $0.6 $12.7 $21.1 Total Liabilities & St

  24. Slide 24: Peer Valuation Comparison

    Slide 24: Peer Valuation Comparison

    = a } & —— Revenue Stock Price 2006, Trai Forward eorrasy icker —"(2/14108) Revenues Grom, —«SMOSEPS PIE PIE (O7E) Hualan Biological ‘ Tavmecrngina’ 002007 $6.78 $46.4 m 2.3% $005 135.20 1127 Biological Prod iological Products : ee 600161 $5.26 $54.5 m 20.5% $005 105.2 131.8 Mean of Above $5.04 $50.

  25. Slide 25: Investment Highlights Summary

    Slide 25: Investment Highlights Summary

    dnveStment Highlights Summary ¢@ Rapidly growing demand for plasma- based products @ Under penetrated, consolidating market ¢@ Securing raw materials supply ¢@ High barriers to entry with strict regulatory environment ¢@ Growing portfolio of high- margin products ¢@ Geographic expansion opportunitie

  26. Slide 26: China Biologic Products Inc. and CCG Elite Investor Relations

    Slide 26: China Biologic Products Inc. and CCG Elite Investor Relations

    China Biologic Products Inc. CCG Elite Investor Relations Inc. Stanley Wong, CEO Crocker Coulson, President No.14 Hushan Road, Tai’an City, 1325 Avenue of the Americas, Suite 2800 271000 Shandong Province, PRC New York, NY 10019 Tel: 86 538-6202306 Tel: 1 (646) 213-1915 IR@chinabiologic.com Crocker.

  27. Slide 27: Thank You

    Slide 27: Thank You

    February 2008 5 & China Biologic Products, Inc. Thank You

Source: SEC EDGAR · 8-K filed Feb 19, 2008

More decks from China Biologic Products Holdings Inc